The surgical treatments for benign prostate hyperplasia (BPH) has been changed and holmium laser enucleation of the prostate (HoLEP) has become to play larger role on it than before. HoLEP research tends to focus on the surgical outcomes but that of surgery education is not fully investigated. In this study, for the purpose of establishing the surgeon educational system of HoLEP, the data from 5 hospitals were investigated in order to find the answer for 1) how many cases do they need for reaching plateau of surgical time? 2) what should we do for prevention of adverse events?
INTRODUCTION AND OBJECTIVES:
The surgical treatments for benign prostate hyperplasia (BPH) has been changed and holmium laser enucleation of the prostate (HoLEP) has become to play larger role on it than before. HoLEP research tends to focus on the surgical outcomes but that of surgery education is not fully investigated. In this study, for the purpose of establishing the surgeon educational system of HoLEP, the data from 5 hospitals were investigated in order to find the answer for 1) how many cases do they need for reaching plateau of surgical time? 2) what should we do for prevention of adverse events?
METHODS: This is a multi-center retrospective study from a total of 1113 cases of HoLEP with full data for analysis as to surgery, preoperative prostate volume, postoperative urination-related factors such as maximal flow rate and residual urine volume and surgery related complication. Surgical procedure and the instrumentation of HoLEP are the same. Complications were categorized as intraoperative, postoperative short-term and long-term ones. The surgeons with less than 20 cases were supervised during HoLEP.
RESULTS: Total 1113 cases were done by 39 surgeons in 5 hospitals in these 10 years with median 24 cases experience. The statistical results showed HoLEP experience positively contributed only to surgical time, enucleation time and reducing postoperative urinary incontinence (p[0.0146, 0.0216 and 0.0405, respectively) even though patients 0 backgrounds are similar. These results are emphasized in 20 cases or more of experiences. However, more number of HoLEP experience did not contribute to morcellation time, resected prostate volume, infectious or noninfectious surgery related complications, or urination related outcomes (p>0.05). Moreover, moderately experienced surgeons (31-50 cases) had higher postHoLEP complications in larger prostate cases, suggesting the possibility that experience may make the surgeons lose caution in a way. CONCLUSIONS: Our data showed 20 cases experience positively contributed to shortened operative time and enucleation time and reducing postoperative urinary incontinence but not to surgery related complications or urination related outcomes as shown by maximum flow rate and post-void residual urine volume. We also found that moderately experienced surgeons had more complications in larger prostate cases. Based on them, we suggest as follows: 1) 20 cases are necessary for learning curve. 2) Reducing complications are always necessary to be paid attention. 3) Moderate experience might lose attention so we should not forget what we think in the initial case. Before the introduction of the thulium, surgery involved bTURP and prostatectomy carried out by two expert surgeons, each having performed more than 500 procedures. The new staff had equal expertise in the laser technique.
Hence, the economic and managerial impact of the introduction of the thulium laser surgery was examined in the treatment of benign prostatic hyperplasia.
METHODS: Together with our Health Directorate, we analysed all the bTURP and prostatectomy carried out in 2016, and we matched them with the ThuVEP carried out in 2017. We examined such factors as time spent in the operating room, length of hospital stay and cost of the procedure. We then examined the total number of procedures carried out from 2016 to the first three months of 2018.
RESULTS: The evidence shows that the number of procedures for prostatic hyperplasia has increased considerably (þ20%). The average duration of hospital stay has gone up from 7.2 (prostatectomy) and from 4.22 (bTURP) to 2 days with an average economy of 53% with TURP and of 72% with prostatectomy. The average cost of hospital stay is €674 per day (a). Surgical times decreased by 52% with prostatectomy and by 35% with TURP.
A ThuVEP cost/procedure is 25% higher than prostatectomy and 22% higher than bTURP. The elimination of transfusions alone has resulted in an economy of €2,353.80. The number of Thulep has increased by 79% from first three months of 2017 to the first three months of 2018.
CONCLUSIONS: Against a minimal increase in the cost/procedure, the introduction of laser surgery has considerably reduced costs in terms of occupation of the surgical room, hospital beds and elimination of requests of transfusions. The introduction of laser technology also entails an increase in the number of patients per specific pathology. The reduction of hospital stay and the increase in case studies suggest an overall optimization as well as rationalisation of human and structural resources.
Surgery is an appropriate treatment option for men with bladder outlet obstruction (BOO) in whom pharmacotherapy has proven unsuccessful. Cost pressures and newer minimally invasive outlet procedures have led to a migration away from the traditional inpatient care setting toward ambulatory surgical centers. We previously demonstrated that patients undergoing BOO surgery in the inpatient setting experience higher rates of 30-day revisits compared to ambulatory procedures. In this context, we aimed to identify predictors of 30-day revisits and associated costs following BOO surgery.
METHODS: All-payer data from the 2014 Healthcare Cost and Utilization Project (HCUP) State Databases from Florida (FL) and New York (NY) were used to identify all patients undergoing an index BOO procedure in the form of transurethral resection (TURP), laser/ photovaporization (PVP), or thermotherapy (TUMT/TUNA). Patient demographics, regional data, 30-day revisit rates, and total charges (converted to costs) associated with revisit were determined. Multivariate logistic regression adjusted for facility clustering was utilized to identify predictors of 30-day revisit.
RESULTS: Of the 15,094 patients undergoing a BOO procedure, 1,444 (9.6%) experienced a 30-day revisit at a median cost of $4263.43. The 30-day revisit rate for cases performed in the inpatient setting was significantly higher than ambulatory procedures (12.0% vs. 8.1%, P<0.001). Predictors of 30-day revisit included older age (OR 1.01, 95% CI 1.00-1. CONCLUSIONS: We demonstrated that index care setting and payer status are independent predictors of 30-day revisit following BOO, with patients undergoing BOO surgery in the inpatient setting and those with Medicare experiencing higher revisit rates. Our findings have important policy implications in the setting of recent value-based purchasing efforts, which seek to reduce variation in non-clinical sources of perioperative costs and outcomes. 
MP01-20 AN IN-VITRO STUDY OF HYBRID LASER FOR PROSTATE SURGERY
Mark Taratkin*, Dmitry Enikeev, Petr Glybochko, Leonid Rapoport, Moscow, Russian Federation; Christopher Netsch, Benedikt Becker, Andreas J. Gross, Hamburg, Germany INTRODUCTION AND OBJECTIVES: The interactions between the laser and tissue depend on the wavelength of the laser. Lasers affect the tissue via its relevant chromophores that absorb energy. In the prostate they are water for Ho:YAG, Tm:YAG and Tm-fiber lasers (TFL) and haemoglobin for the Greenlight (KTP) laser and blue diode laser (BDL). Combining the two lasers (TFLþBDL) with different target chromophores (water and hemoglobin) may have potential benefits for prostate surgery, namely less carbonization and faster vaporization. The aim of this study was to investigate the potential of a hybrid (TFLþBDL) laser vs. TFL and Ho:YAG lasers in vitro.
METHODS: Fresh non-frozen porcine kidney was used as the model for the prostate to compare 3 lasers with an average power of 120W: a Ho:YAG laser, a TFL and a hybrid TFLþBDL (Table 1) . In all cases, a 600 µm cleaved laser fiber was employed. A motorized XY translation stage with fixed fiber holder for control of cutting speed (2mm/s and 5 mm/s) was used. All samples were put in tissue holders with 0.5AE0.1 mm gap between the fiber and tissue. Five incisions of kidney in saline solution with each laser were made. Lactate dehydrogenase (LDH) staining of the embedded specimens was performed to determine incision depth, zones of vaporization, zones of coagulation and visible carbonization rate (from 0 to 3).
RESULTS: Laser properties, laser settings and pathology results are shown in Table 1 . Hybrid laser (TFLþBDL) produced the deepest incisions and provided the fastest vaporization among the investigated lasers with little to no carbonization and limited coagulation depth. All these facts make it a perfect tool for tissue vaporization.
CONCLUSIONS: A hybrid TFL þ BDL makes deeper and faster incisions than TFL and Ho:YAG lasers. Interestingly, it also produces a smaller carbonization zone and limits coagulation depth.
